Bing-Yan Zhu,Michael Siu,Steven R. Magnuson,Richard Pastor,He Haiying,Xiao Yisong,Zheng Jifu,Xu Xing,Zhao Junping,Wendy Liu
申请号：
US14878774
公开号：
US20160024089A1
申请日:
2015.10.08
申请国别(地区):
US
年份:
2016
代理人:
摘要：
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
